These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23169228

  • 61. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
    Stocchi F, Nordera G, Marsden CD.
    Clin Neuropharmacol; 1997 Apr; 20(2):95-115. PubMed ID: 9099462
    [Abstract] [Full Text] [Related]

  • 62. Rapid treatment of "wearing off" in Parkinson's disease.
    Swope DM.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
    [Abstract] [Full Text] [Related]

  • 63. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D.
    Nervenarzt; 2005 Jun 23; 76(6):681-9. PubMed ID: 15592807
    [Abstract] [Full Text] [Related]

  • 64. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L, Albani G, Calderoni S, Baudo S, Lopiano L, Rizzone M, Astolfi V, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A.
    Neurol Sci; 2002 Sep 23; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [Abstract] [Full Text] [Related]

  • 65. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 23; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 66. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Feb 23; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T, Postma AG, Drent M.
    Parkinsonism Relat Disord; 2010 Jan 23; 16(1):71-2. PubMed ID: 19524477
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
    Luthra PM, Kumar JB.
    Mini Rev Med Chem; 2012 Dec 23; 12(14):1556-64. PubMed ID: 22697513
    [Abstract] [Full Text] [Related]

  • 75. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY.
    Clin Neuropharmacol; 1996 Jun 23; 19(3):193-201. PubMed ID: 8726538
    [Abstract] [Full Text] [Related]

  • 76. [Hallucinations in Parkinson's disease].
    Moser A, Hagenah J, Kömpf D.
    Nervenarzt; 2003 Apr 23; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [Abstract] [Full Text] [Related]

  • 77. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C, Zangger I, Fischer G.
    Schweiz Rundsch Med Prax; 1992 Aug 25; 81(35):1011-5. PubMed ID: 1410978
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Othello syndrome in patients with Parkinson's disease.
    Georgiev D, Danieli A, Ocepek L, Novak D, Zupancic-Kriznar N, Trost M, Pirtosek Z.
    Psychiatr Danub; 2010 Mar 25; 22(1):94-8. PubMed ID: 20305599
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.